CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Researchers sought to evaluate preferences related to treatment features of BCMA-directed bispecific antibodies and CAR-T therapy.

The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Soquelitinib is well-positioned as a first-in-class oral ... of adenosine A2A receptor antagonist for the treatment of cancer with ciforadenant. This includes our Phase 1b/2 clinical trial that ...

NLRP3 is a member of a family of proteins known as inflammasome receptors and is a key component ... inhibits the production of pro-inflammatory cytokines like interleukin-1 beta and interleukin ...

TuHURA Biosciences, Inc.  ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that an abstract highlighting ...